Advertisement

Topics

OpenBiome Partnering with Finch Therapeutics to Enable FDA Approval of a Fecal Transplant Treatment for Recurrent C. Difficile Infection

09:00 EST 23 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
The stool bank will also continue providing fecal transplant preparations to clinicians and researchers OpenBiome, a public stool bank, announced today that it has entered into a collaboration with Finch Therapeutics, a micr...

Other Sources for this Article

OpenBiome
Alex Scheeler, 617-575-2201 x 716
media@openbiome.org
alex@openbiome.org

NEXT ARTICLE

More From BioPortfolio on "OpenBiome Partnering with Finch Therapeutics to Enable FDA Approval of a Fecal Transplant Treatment for Recurrent C. Difficile Infection"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...